Article Text

Download PDFPDF
Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants
  1. N V Subhedara,
  2. S W Ryana,
  3. N J Shawb
  1. aInstitute of Child Health, University of Liverpool, bRegional Neonatal Intensive Care Unit, Liverpool Women’s Hospital
  1. Correspondence to: Dr N V Subhedar, Regional Neonatal Intensive Care Unit, Liverpool Women’s Hospital, Crown Street, Liverpool L8 7SS.

Abstract

AIM To determine whether treatment with inhaled nitric oxide (NO) and/or dexamethasone reduces the incidence of chronic lung disease (CLD) and/or death in high risk preterm infants.

METHODS Infants below 32 weeks of gestation were recruited at 96 hours of age if they were deemed to be at high risk of developing CLD. Infants were randomly assigned to one of four treatment groups using a factorial design: (1) 5–20 parts per million inhaled NO for 72 hours; (2) 0.5–1 mg/kg/day intravenous dexamethasone for 6 days; (3) both drugs together; (4) continued conventional management.

RESULTS Forty two infants were randomised: 10 infants received inhaled NO alone; 11 dexamethasone alone; 10 both treatments; and 11 neither treatment. There was no difference in the combined incidence of CLD and/or death before discharge from hospital between either infants treated with inhaled NO and controls (RR 1.05, 95% CI 0.84–1.25), or those treated with dexamethasone and controls (RR 0.95, 95% CI 0.79–1.18).

CONCLUSIONS At 96 hours of age, neither treatment with inhaled NO nor dexamethasone prevented CLD or death.

  • randomised controlled trial
  • nitric oxide
  • dexamethasone
  • chronic lung disease

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes